What is claimed:

1. A method for treating a patient comprising administering an injection of a local anesthetic and an alpha-2-adrenergic agonist.

2. The method of claim 1, wherein said local anesthetic is selected from the group consisting of Chloroprocaine, Procaine, Novocaine, Tetracaine, Amethocaine, lidocaine, prilocaine, mepivacaine, bupivicaine, levobupivacaine, ropivacaine, dibucaine, etidocine, Benzocaine, Cocaine, Cyclomethycaine, Dimethocaine/Larocaine, Piperocaine, Propoxycaine, Proparacaine, Trimecaine and combinations thereof.

3. The method of claim 1, wherein said alpha-2-adrenergic agonist is selected from the group consisting of Guanfacine, Guanabenz, Guanoxabenz, Guanethidine, Xylazine, Tizanidine, Methyldopa, clonidine, Fadolmidine, Dexmedetomidine and combinations thereof.

4. The method of claim 1, wherein said local anesthetic is mixed with said alpha-2-adrenergic agonist into a solution.

5. The method of claim 1, wherein said local anesthetic is bupivacaine.

6. The method of claim 1, wherein said alpha-2-adrenergic agonist is clonidine.

7. The method of claim 1, wherein said injection is administered as a right sided cervical sympathetic ganglion injection.

8. The method of claim 1, wherein said injection is administered as a left sided cervical sympathetic ganglion injection.

9. The method of claim 1, wherein said injection is administered at cervical vertebrae 6.

10. The method of claim 1, wherein said injection is administered at cervical vertebrae 7.

11. The method of claim 1, wherein said injection is administered at cervical vertebrae 7.

12. The method of claim 1, wherein said local anesthetic is administered in a range from 0.005 µg /cc to 40 µg /cc.

13. The method of claim 1, wherein said alpha-2-adrenergic agonist is administered in a range from 0.5 to 1000 µg /cc.

14. The method of claim 1, wherein said injection is administered to treat patients having post-traumatic stress disorder.

15. The method of claim 1, wherein said injection is administered to treat patients having hot flashes.

16. The method of claim 1, wherein the administering of said injection is intracerebral, epidural, topical, enteral, parenteral, intramuscular, intradermal, intravenous, subcutaneous or intrathecal.

17. A kit containing said local anesthetic and said alpha-2-adrenergic agonist of claim 1, comprising at least one vial.

18. The kit of claim 17, additionally comprising at least one syringe.

19. The kit of claim 17, additionally comprising at least one needle.

20. The kit of claim 17, additionally comprising a package insert.

21. The kit of claim 17, additionally comprising a manual for pre and post injection screening for PTSD and hot flashes diagnosis.

22. A method for treating a patient experiencing post-traumatic stress disorder or hot flashes comprising:

administering a cervical sympathetic ganglion injection comprising a combination of a long lasting local anesthetic and clonidine.

23. The method of claim 22, wherein said long lasting local anesthetic is bupivacaine.

24. The method of claim 22, wherein said combination is made in a preservative free sterile saline solution.

25. A composition comprising a combination of a bupivacaine and clonidine, wherein said combination is administered to a patient via an injection to a cervical sympathetic ganglion.

What is claimed:

1. A local anesthetic and an alpha-2-adrenergic agonist for use in the treatment of a disease, wherein the local anesthetic and an alpha-2-adrenergic agonist is to be administered via injection.

2. The use of a local anesthetic and an alpha-2-adrenergic agonist in the manufacture of a medicament for the treatment of post-traumatic stress disorder or hot flashes.

3. The local anesthetic and an alpha-2-adrenergic agonist of claim 1 or the use of claim 2, wherein said local anesthetic is selected from the group consisting of Chloroprocaine, Procaine, Novocaine, Tetracaine, Amethocaine, lidocaine, prilocaine, mepivacaine, bupivicaine, levobupivacaine, ropivacaine, dibucaine, etidocine, Benzocaine, Cocaine, Cyclomethycaine, Dimethocaine/Larocaine, Piperocaine, Propoxycaine, Proparacaine, Trimecaine and combinations thereof.

4. The local anesthetic and an alpha-2-adrenergic agonist of claim 1 or the use of claim 2, wherein said alpha-2-adrenergic agonist is selected from the group consisting of Guanfacine, Guanabenz, Guanoxabenz, Guanethidine, Xylazine, Tizanidine, Methyldopa, clonidine, Fadolmidine, Dexmedetomidine and combinations thereof.

5. The local anesthetic and an alpha-2-adrenergic agonist of claim 1 or the use of claim 2, wherein said local anesthetic is mixed with said alpha-2-adrenergic agonist into a solution.

6. The local anesthetic and an alpha-2-adrenergic agonist of claim 1 or the use of claim 2, wherein said local anesthetic is bupivacaine.

7. The local anesthetic and an alpha-2-adrenergic agonist of claim 1 or the use of claim 2, wherein said alpha-2-adrenergic agonist is clonidine.

8. The local anesthetic and an alpha-2-adrenergic agonist of claim 1 or the use of claim 2, wherein said injection is to be administered as a right sided cervical sympathetic ganglion injection.

9. The local anesthetic and an alpha-2-adrenergic agonist of claim 1 or the use of claim 2, wherein said injection is to be administered as a left sided cervical sympathetic ganglion injection.

10. The local anesthetic and an alpha-2-adrenergic agonist of claim 1 or the use of claim 2, wherein said injection is to be administered at cervical vertebrae 6.

11. The local anesthetic and an alpha-2-adrenergic agonist of claim 1 or the use of claim 2, wherein said injection is to be administered at cervical vertebrae 3.

12. The local anesthetic and an alpha-2-adrenergic agonist of claim 1, wherein said injection is to be administered at cervical vertebrae 7.

13. The local anesthetic and an alpha-2-adrenergic agonist of claim 1 or the use of claim 2, wherein said local anesthetic is to be administered in a range from 0.005 µg /cc to 40 µg /cc.

14. The local anesthetic and an alpha-2-adrenergic agonist of claim 1 or the use of claim 2, wherein said alpha-2-adrenergic agonist is to be administered in a range from 0.5 to 1000 µg/cc.

15. The local anesthetic and an alpha-2-adrenergic agonist of claim 1 or the use of claim 2, wherein said injection is to be administered to treat patients having post-traumatic stress disorder.

16. The local anesthetic and an alpha-2-adrenergic agonist of claim 1 or the use of claim 2, wherein said injection is to be administered to treat patients having hot flashes.

17. The local anesthetic and an alpha-2-adrenergic agonist of claim 1 or the use of claim 2, wherein the administering of said injection is intracerebral, epidural, topical, enteral, parenteral, intramuscular, intradermal, intravenous, subcutaneous or intrathecal.

18. The use of a kit comprising the local anesthetic and alpha-2-adrenergic agonist of claim 1 in the manufacture of a medicament for the treatment or pre and post injection screening of PTSD or hot flashes, wherein said kit additionally comprises at least one vial.

19. The use of claim 18, wherein the kit additionally comprises at least one syringe.

20. The use of claim 18, wherein the kit additionally comprises at least one needle.

21. The use of claim 18, wherein the kit additionally comprises a package insert.

22. A combination of a long lasting local anesthetic and clonidine for use in the treatment of post-traumatic stress disorder or hot flashes, wherein the combination of a long lasting local anesthetic and clonidine is to be administered via a cervical sympathetic ganglion injection.

23. The use of a combination of a long lasting local anesthetic and clonidine in the manufacture of a medicament for the treatment of post-traumatic stress disorder or hot flashes.

24. The combination of a long lasting local anesthetic and clonidine of claim 22 or the use of claim 23, wherein the long lasting local anesthetic is bupivacaine.

25. The combination of a long lasting local anesthetic and clonidine of claim 22 or the use of claim 23, wherein the combination is made in a preservative free sterile saline solution.

26. A composition comprising a combination of a bupivacaine and clonidine, wherein said combination is to be administered to a patient via an injection to a cervical sympathetic ganglion.